home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

About Us

WHO WE ARE

To earn trust, every day.

Schering-Plough is committed to earning the trust of doctors, patients and customers every day. Our colleagues worldwide believe that trust is not easily granted, and that is the reason we focus each day on becoming a champion for our stakeholders.

During the past five years, Schering-Plough has been building a new kind of health care company. Throughout Schering-Plough, there’s a desire to build long-term relationships with our stakeholders based on mutual confidence. This is evident in many ways. Our scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and well-being of people around the world. Our sales professionals, marketing teams, colleagues working at our plants and others throughout the organization at all levels of responsibility take each day as a fresh opportunity to earn trust.

All of this takes hard work, sharp execution, integrity and transparency on the part of Schering-Plough’s colleagues. Our global team is working to sustain and expand innovative new treatments. We’re determined to do our part to increase access to better health care for all people. And, we are focused on becoming the best in three key strategic areas: people, products and processes.

We’re beginning to see the results of our efforts, but believe the best is yet to come. The test of being a true champion is to never give up and to passionately strive for even better outcomes. From our perspective as a health care company, that means helping people around the world live better and live longer.


Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough